Alume Biosciences is a technology company.
Alume Biosciences has raised $6.0M across 1 funding round.
Alume Biosciences has raised $6.0M in total across 1 funding round.
Alume Biosciences is a privately-held biotechnology company developing nerve illumination technology to enhance surgical precision and outcomes.[1][2][4] Their flagship product, ALM-488 (also referred to as bevonescein), is a peptide-dye conjugate administered intravenously 60 minutes before surgery, causing nerves to fluoresce and become visible under standard surgical lighting, helping surgeons identify and avoid them to prevent damage like paralysis or numbness.[1][3][5][6] This addresses a critical problem in surgeries where unintended nerve injury affects patient quality of life, operative times, and recovery; ALM-488 is in concurrent Phase 3 clinical trials with FDA submission targeted for 2025, showing strong growth momentum toward commercialization.[1][3]
Alume Biosciences emerged from a collaboration between CEO Quyen Nguyen, a leading surgeon and expert in fluorescent technologies, and Roger Y. Tsien (1952-2016), Nobel Prize winner in Chemistry for green fluorescent protein development.[3] Their partnership began focused on nerve-illuminating agents to aid surgeons, building on Tsien's breakthroughs and Nguyen's clinical expertise, including her Presidential Early Career Award and TED Talk on the technology.[3] The company launched formally in 2016, advancing ALM-488 from early development—starting clinical trials in 2022, with Phase 3 underway by 2023-2024—marking pivotal traction toward regulatory approval.[1][3]
Alume rides the wave of precision surgery and intraoperative imaging trends, where fluorescence-guided techniques reduce complications in high-stakes procedures like oncology, ENT, and neurology surgeries.[2][3] Timing aligns with rising demand for nerve-sparing tech amid aging populations and minimally invasive procedures, amplified by post-pandemic focus on outcome optimization and shorter hospital stays.[1][6] Market forces favor Alume: nerve injury affects millions annually, creating a multi-billion opportunity in surgical adjuncts, while their tech influences the ecosystem by setting standards for visual aids, potentially accelerating adoption of fluorescent agents across biotech and medtech.[1][2]
Alume is poised for a transformative 2025 with potential FDA approval of ALM-488, enabling commercialization and expansion into broader surgical applications.[1][3] Trends like AI-enhanced imaging and personalized medicine will amplify their tech, while partnerships with device makers could scale impact. Their influence may evolve from niche innovator to ecosystem leader in nerve preservation, redefining surgical safety and solidifying biotech's role in patient-centered precision. This positions Alume as a high-momentum player bridging lab breakthroughs to operating rooms worldwide.[3][6]
Alume Biosciences has raised $6.0M in total across 1 funding round.
Alume Biosciences's investors include BioBrit.
Alume Biosciences has raised $6.0M across 1 funding round. Most recently, it raised $6.0M Series A in April 2020.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Apr 1, 2020 | $6.0M Series A | BioBrit |